Esophagitis Clinical Trial
Official title:
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer With Radiation With or Without Chemotherapy
This study will evaluate whether a Whole Food Intervention reduces the frequency or severity
of esophagitis in patients receiving treatment for non-small cell lung cancer.
The Whole Food Intervention consists of yogurt, butter, honey, vanilla, and glutamine with 3
portioning cups, equal to approximately 12 ounces, taken daily before starting radiation
therapy.
The proposal is a one center, open label, randomized pilot study to evaluate the safety,
tolerability and compliance of a Whole Food Intervention with Standard of Care for patients
with non-small cell lung cancer. The primary objectives are:
1. To determine whether patients will use a Whole Food Intervention 4-6 times daily, and
2. To determine whether the Whole Food Intervention will reduce the incidence of grade 2
or greater esophagitis from 75% historically seen to 25% .
3. To determine whether Whole Food Intervention will reduce the incidence of treatment
breaks from >19% to < 10% (see section 9 for comments)
This Whole Food Intervention will be taken by mouth before the start of radiation therapy,
with or without chemotherapy and for the entire treatment therapy.
Esophagitis-related pain and reduction of oral intake will be quantified by using validated
assessment tools. Weight loss or gain, diarrhea, constipation or no change in bowel function
and the use of conventional medication for radiation-induced esophagitis will be recorded.
Chart review and patient questionnaires will be used to establish whether a treatment break
or dose reduction for radiation of chemotherapy was required due to radiation
esophagitis-related symptoms. Complete Chemistry Profile and Complete Blood Count will be
extracted from the patients' medical oncologist's or radiation oncologist's records. The
patient will continue to use standard esophagitis therapies if desired as prescribed by the
treating oncology physician.
The Whole Food Intervention consists of yogurt, butter, honey, vanilla, and glutamine with 3
portioning cups, equal to approximately 12 ounces, taken daily before starting radiation
therapy. A questionnaire will be used to record symptoms and doses taken. The patient will
continue to use standard esophagitis therapies as prescribed by the treating oncology
physician.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00272818 -
Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
|
||
Recruiting |
NCT05326113 -
The Effect of Physiotherapy on Post POEM Reflux
|
N/A | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Completed |
NCT00256529 -
Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia
|
N/A | |
Completed |
NCT00123630 -
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
|
Phase 2 | |
Completed |
NCT00081315 -
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00471094 -
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
|
Phase 2 | |
Completed |
NCT00579410 -
Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule
|
N/A | |
Recruiting |
NCT05109819 -
Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression.
|
N/A | |
Withdrawn |
NCT01824199 -
CYP2C19 Genotype Predictor of Gastric Acid Suppression
|
Early Phase 1 | |
Completed |
NCT01556919 -
Esophageal Monitoring Device for Assessing Mucosal Impedance
|
||
Active, not recruiting |
NCT03835663 -
The Bacterial Composition of the Stomach in Reflux Disease
|
||
Completed |
NCT00195208 -
Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT00175045 -
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
|
Phase 2 | |
Completed |
NCT05129670 -
Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum
|
N/A | |
Recruiting |
NCT05004155 -
Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
|
||
Completed |
NCT03228147 -
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
|
N/A | |
Completed |
NCT00133770 -
Intravenous (IV) Pantoprazole in Erosive Esophagitis
|
Phase 4 | |
Completed |
NCT01322633 -
Risk of Cancer Among Pantoprazole Users
|
N/A |